Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial.
Junqiang Chen, Xiao Chang, Wenyang Liu, Xiaomin Wang, Xiaolin Ge, Ke Liu, Lei Deng, Miaomiao Hu, Jianchao Lu, Wei Wang, Haiwen Zhou, Shuai Qie, Jihong Zhang, Weiming Han, Wenqing Wang, Zongmei Zhou, Xin Wang, Jun Liang, Nan Bi, Tao Zhang, Jianyang Wang, Yirui Zhai, Lan Wang, Yu Lin, Yidian Zhao, Qingsong Pang, Xinchen Sun, Yonggang Shi, Kaixian Zhang, Ling Li, Qifeng Wang, Minghe Li, Hongyun Shi, Zhilong Yu, Wei Deng, Chun Han, Junjie Wang, Wanqing Chen, Wencheng Zhang, Zefen Xiao, Jing-Jin-Ji Esophageal, Esophagogastric Cancer Radiotherapy Oncology Group 3JECROG
Radiother Oncol 218 111334
摘要
摘要
PURPOSE: This study reports the long-term outcomes of simultaneous integrated boost radiotherapy (SIB-RT) combined with oral S-1 chemotherapy (CRTCT) in inoperable patients aged ≥ 70 years with inoperable esophageal squamous cell carcinoma (ESCC). METHODS: In this multicenter, phase III randomized trial, patients with inoperable, locally advanced stage II-IV ESCC were randomized to receive either CRTCT or RT alone. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), restricted mean survival time (RMST), and patterns of failure. RESULTS: After a median follow-up of 75 months, patients in the CRTCT group had longer OS than those in the RT group (hazard ratio (HR), 0.74; 95 % confidence interval (CI), 0.57-0.95; P = 0.02), with better 5-year OS rates (34.1 % vs. 23.6 %,P = 0.02), PFS (31.1 % vs. 20.9 %,P = 0.02), and RMST (33.0 vs. 27.0 months,P = 0.02). CRTCT's effect on OS stabilized over 5 years. Locoregional failure was lower in the CRTCT group (HR, 0.64; 95 % CI, 0.45-0.92; P = 0.02), with similar distant and mixed failure risks. CONCLUSIONS: SIB-RT combined with oral S-1 chemotherapy significantly improved long-term survival and therefore might be considered a standard of care for elderly patients with inoperable ESCC. TRIAL REGISTRATION Clinical Trials.gov Identifier: NCT0297969.
KM 提取结果
0 个 Figure · 0 个 KM 面板